-
公开(公告)号：KR1020100011963A
公开(公告)日：2010-02-03
申请号：KR1020090068571
申请日：2009-07-27
Applicant: 국립암센터
CPC classification number: A61K31/198
Abstract: PURPOSE: A composition for suppressing transglutaminase containing NDGA(Nordihydroguaiaretic acid) is provided to suppress transglutaminase activity without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by transglutaminase activity increase contains NDGA of chemical formula 1 as an active ingredient. The NDGA is isolated from Larrea divaricata Cav. Diseases caused by transglutaminase activity is neural diseases, inflammatory diseases, or cancer. The neural diseases are Alzheimer disease, multi-infarct dementia, hypothyrodism, alcoholic dementia, Huntingtun disease, or Parkinson's disease.
Abstract translation: 目的：提供一种用于抑制含有NDGA（Nordihydroguaiaretic acid）的转谷氨酰胺酶的组合物，以抑制转谷氨酰胺酶的活性而无副作用。 构成：用于预防或治疗由转谷氨酰胺酶活性增加引起的疾病的药物组合物含有化学式1的NDGA作为活性成分。 NDGA与Larrea divaricata Cav分离。 由转谷氨酰胺酶活性引起的疾病是神经疾病，炎性疾病或癌症。 神经疾病是阿尔茨海默病，多发性梗塞性痴呆，甲状腺功能低下，酒精性痴呆，亨廷顿病或帕金森病。
-
公开(公告)号：KR101920163B1
公开(公告)日：2018-11-19
申请号：KR1020170094694
申请日：2017-07-26
Abstract: 본발명은 c-Myc/Max/DNA 복합체형성을억제하는활성을갖는특정화학구조의화합물또는이의약학적으로허용가능한염을유효성분으로포함하는암의치료또는예방용약학조성물을제공한다. 본발명은본 발명에따른약학조성물의암 치료또는예방용의약용도를제공한다. 본발명은또한본 발명에따른화합물, 이의염 또는이들을포함하는조성물의유효한양을치료가필요한개체에게투여하는것을포함하는암의치료또는예방방법을제공한다.
-
-
公开(公告)号：KR1020120079254A
公开(公告)日：2012-07-12
申请号：KR1020110000445
申请日：2011-01-04
IPC: A61K31/4704 , A61K31/47 , A61P35/02 , A61P35/00
CPC classification number: A61K31/47
Abstract: PURPOSE: A pharmaceutical composition containing 4-quinolinone derivatives and a Myc protein activation inhibitor containing the derivatives is provided to suppress complex formation of Myc/Max/DNA and to induce cell cycle arrest. CONSTITUTION: An Myc protein activation inhibitor contains 4-quinoline derivative of chemical formula 1. The derivative of chemical formula 1 suppresses formation of Myc/Max/DNA complex formation. A pharmaceutical composition for treating leukemia contains the derivative as an active ingredient. The pharmaceutical composition for treating leukemia contains pharmaceutically acceptable carrier. The pharmaceutical composition is manufactured in the form of troches, lozenge, aqueous or oil suspension, powder or granule, emulsion, hard or soft capsule, or elixir.
Abstract translation: 目的：提供含有4-喹啉酮衍生物和含有这些衍生物的Myc蛋白激活抑制剂的药物组合物，以抑制Myc / Max / DNA的复合物形成并诱导细胞周期停滞。 构成：Myc蛋白激活抑制剂含有化学式1的4-喹啉衍生物。化学式1的衍生物抑制Myc / Max / DNA复合体形成。 用于治疗白血病的药物组合物含有该衍生物作为活性成分。 用于治疗白血病的药物组合物含有药学上可接受的载体。 药物组合物以锭剂，锭剂，水性或油性悬浮液，粉末或颗粒剂，乳剂，硬或软胶囊或酏剂的形式制备。
-
公开(公告)号：KR101145930B1
公开(公告)日：2012-05-15
申请号：KR1020070056811
申请日：2007-06-11
Applicant: 국립암센터
IPC: A61K31/216 , A61K31/045 , A61P35/00
CPC classification number: A61K31/216
Abstract: 본 발명은 클로로겐산, 그의 약제학적으로 허용가능한 염 또는 그의 유도체를 포함하는 트란스글루타미나제 억제제에 관한 것으로, 더욱 상세하게는 이상 발현의 경우 질병의 병리적 기전에 관여하는 트란스글루타미나제의 작용을 억제하기 위한 클로로겐산, 그의 약제학적으로 허용가능한 염 또는 그의 유도체를 포함하는 트란스글루타미나제 억제제와 이들의 신규한 용도에 관한 것이다. 본 발명에 따르면, 클로로겐산, 그의 약제학적으로 허용가능한 염 또는 그의 유도체를 활성 성분으로 포함하는 것을 특징으로 하는 트란스글루타미나제 억제제 및 트란스글루타미나제의 억제방법을 제공할 수 있다. 본 발명에 따른 클로로겐산, 그의 약제학적으로 허용가능한 염 또는 그의 유도체를 이용하여 트란스글루타미나제를 억제하는 신규한 방법은 트란스글루타미나제가 이상 발현되는 질환을 가진 대상에게 안전한 방법으로 부작용없이 용이하게 적용되어 트란스글루타미나제를 억제하는 효과를 얻을 수 있다.
클로로겐산, 트란스글루타미나제-
Patent Agency Ranking
公开(公告)号：KR1020080108796A
公开(公告)日：2008-12-16
申请号：KR1020070056811
申请日：2007-06-11
Applicant: 국립암센터
IPC: A61K31/216 , A61K31/045 , A61P35/00
CPC classification number: A61K31/216
Abstract: A transglutaminase inhibitor including chlorogenic acid +is provided to stably apply to a patient having the disease in which transglutaminase is expressed abnormally without side effects, thereby suppressing transglutaminase. The transglutaminase inhibitor contains a material selected from the group consisting of chlorogenic acid and their salt and their derivative, wherein the salt of chlorogenic acid is chlorogenic acid sodium or chlorogenic acid potassium. The material selected from the group consisting of chlorogenic acid and their salt and their derivative is used to inhibit the activity of transglutaminase.
Abstract translation: 提供了包含绿原酸+的转谷氨酰胺酶抑制剂，以稳定地应用于具有异丙酰肌酸异常表达的疾病的患者，而没有副作用，从而抑制转谷氨酰胺酶。 转谷氨酰胺酶抑制剂含有选自绿原酸及其盐及其衍生物的物质，其中绿原酸盐为绿原酸钠或绿原酸钾。 选自绿原酸及其盐及其衍生物的材料用于抑制转谷氨酰胺酶的活性。
-
公开(公告)号：KR1020150083353A
公开(公告)日：2015-07-17
申请号：KR1020140002991
申请日：2014-01-09
Applicant: 국립암센터
IPC: A61K31/47 , A61K31/4704 , A61P35/00
CPC classification number: A61K31/47 , A61K9/0034
Abstract: 본발명은경요도적주입용방광암예방또는치료용약제학적조성물에관한것으로, 보다상세하게는하기화학식 1로표시되는화합물또는이의약제학적으로허용되는염을포함하는경요도적주입용방광암치료용약제학적조성물에관한것이다.
Abstract translation: 本发明涉及一种用于预防或治疗膀胱癌的经尿道注射用药物组合物，更具体地，涉及用于治疗膀胱癌的经尿道注射用药物组合物，其包含化学式1表示的化合物或其药学上可接受的盐。
-
公开(公告)号：KR20180013755A
公开(公告)日：2018-02-07
申请号：KR20170094694
申请日：2017-07-26
Abstract: 본발명은 c-Myc/Max/DNA 복합체형성을억제하는활성을갖는특정화학구조의화합물또는이의약학적으로허용가능한염을유효성분으로포함하는암의치료또는예방용약학조성물을제공한다. 본발명은본 발명에따른약학조성물의암 치료또는예방용의약용도를제공한다. 본발명은또한본 발명에따른화합물, 이의염 또는이들을포함하는조성물의유효한양을치료가필요한개체에게투여하는것을포함하는암의치료또는예방방법을제공한다.
Abstract translation: 本发明提供具有抑制形成，或药物组合物用于癌症治疗或预防，包括上可接受的盐的活性的特定化学结构的c-Myc的/最大/ DNA复合化合物uiyakhak敌人，作为活性成分。 本发明提供了用于治疗或预防根据本发明的药物组合物的癌症的药物。 本发明还提供了用于治疗或预防癌症的方法，其包含向有需要的受试者施用有效量的根据本发明的化合物，其盐或包含其的组合物。
-
公开(公告)号：KR1020110006534A
公开(公告)日：2011-01-20
申请号：KR1020090064219
申请日：2009-07-14
Applicant: 국립암센터
IPC: A61K31/194 , A61K31/336 , A61P35/00 , A61P29/00
Abstract: PURPOSE: A method for inducing remodeling keratin in cancer cells or inflammatory cells is provided to develop a therapeutic agent for metastatic cancer. CONSTITUTION: A compound of chemical formula 1 or 2 is used for inducing keratin remodeling in cancer cells or inflammatory cells. A method for screening an anticancer drug comprises: a step of simultaneously or gradually treating the compound and test compound to cancer cells; a step of measuring keratin remodeling degree in the cancer cells; and a step of determining a compound which functions as an inhibitor for cancer metastasis in case of suppressing keratin remodeling by treatment of the test compound. A composition for inducing cancer metastasis contains the compound of chemical formula 1 or 2.
Abstract translation: 目的：提供一种在癌细胞或炎性细胞中诱导重塑角蛋白的方法，以开发转移性癌症的治疗剂。 构成：化学式1或化合物2用于诱导癌细胞或炎性细胞中的角蛋白重塑。 筛选抗癌药物的方法包括：同时或逐渐地将所述化合物和试验化合物处理至癌细胞的步骤; 测定癌细胞角蛋白重塑度的步骤; 以及在通过治疗化合物抑制角蛋白重塑的情况下，测定作为癌症转移抑制剂起作用的化合物的工序。 用于诱导癌症转移的组合物含有化学式1或化合物2。
-
20.发明公开에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 无效用于预防或治疗包含乙酸的转谷氨酰胺酶相关疾病的药物组合物，以及使用该方法预防或治疗转谷氨酰胺酶相关疾病的方法
公开(公告)号：KR1020100060189A
公开(公告)日：2010-06-07
申请号：KR1020080118688
申请日：2008-11-27
Applicant: 국립암센터
IPC: A61K31/192 , A61P35/00
CPC classification number: A61K31/192
Abstract: PURPOSE: A transglutaminase inhibitor containing ethacrynic acid and a pharmaceutically acceptable salt thereof is provided to prevent and treat transglutaminase overexpression-related diseases without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by enhanced transglutaminase activation contains ethacrynic acid or a pharmaceutically acceptable salt thereof. Diseases are inflammatory diseases, cancer, or neural disorders. The inflammatory disease is chronic inflammatory disease, sepsis, or autoimmunity myositis. The neural disorder is Alzheimer disease, Huntingtun disease, or Parkinson's disease.
Abstract translation: 目的：提供含有ethacrynic酸及其药学上可接受的盐的转谷氨酰胺酶抑制剂，用于预防和治疗转谷氨酰胺酶过表达相关疾病而没有副作用。 构成：用于预防或治疗由增强的转谷氨酰胺酶活化引起的疾病的药物组合物含有乙酰酸或其药学上可接受的盐。 疾病是炎性疾病，癌症或神经障碍。 炎性疾病是慢性炎性疾病，败血症或自身免疫性肌炎。 神经障碍是阿尔茨海默病，亨廷顿病或帕金森病。
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.029 seconds)
